406 related articles for article (PubMed ID: 29648739)
21. Recommendations of the Medicare Payment Advisory Commission (MEDPAC) on the Health Care Delivery System: the impact on interventional pain management in 2014 and beyond.
Manchikanti L; Benyamin RM; Falco FJ; Hirsch JA
Pain Physician; 2013; 16(5):419-40. PubMed ID: 24077189
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
Erath A; Dusetzina SB
JAMA Netw Open; 2020 Apr; 3(4):e203969. PubMed ID: 32338754
[TBL] [Abstract][Full Text] [Related]
23. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
[TBL] [Abstract][Full Text] [Related]
24. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.
Hopson S; Saverno K; Liu LZ; AL-Sabbagh A; Orazem J; Costantino ME; Pasquale MK
J Manag Care Spec Pharm; 2016 Feb; 22(2):122-30. PubMed ID: 27015251
[TBL] [Abstract][Full Text] [Related]
25. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system.
Brouwer E; Yeung K; Barthold D; Hansen R
J Manag Care Spec Pharm; 2021 Jun; 27(6):732-742. PubMed ID: 34057391
[No Abstract] [Full Text] [Related]
26. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
[TBL] [Abstract][Full Text] [Related]
27. Out-of-pocket costs and oral cancer medication discontinuation in the elderly.
Kaisaeng N; Harpe SE; Carroll NV
J Manag Care Spec Pharm; 2014 Jul; 20(7):669-75. PubMed ID: 24967520
[TBL] [Abstract][Full Text] [Related]
28. Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic Myelogenous Leukemia.
Talon B; Calip GS; Lee TA; Sharp LK; Patel P; Touchette DR
JCO Oncol Pract; 2021 Nov; 17(11):e1811-e1820. PubMed ID: 33961496
[TBL] [Abstract][Full Text] [Related]
29. Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions.
Doshi JA; Li P; Ladage VP; Pettit AR; Taylor EA
Am J Manag Care; 2016 Mar; 22(3):188-97. PubMed ID: 27023024
[TBL] [Abstract][Full Text] [Related]
30. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
[TBL] [Abstract][Full Text] [Related]
31. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
32. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
33. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
34. Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007-11.
Trish E; Joyce G; Goldman DP
Health Aff (Millwood); 2014 Nov; 33(11):2018-24. PubMed ID: 25367998
[TBL] [Abstract][Full Text] [Related]
35. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
[TBL] [Abstract][Full Text] [Related]
36. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
[No Abstract] [Full Text] [Related]
37. Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007.
Briesacher BA; Zhao Y; Madden JM; Zhang F; Adams AS; Tjia J; Ross-Degnan D; Gurwitz JH; Soumerai SB
Med Care; 2011 Sep; 49(9):834-41. PubMed ID: 21544002
[TBL] [Abstract][Full Text] [Related]
38. Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.
Davidoff AJ; Hendrick FB; Zeidan AM; Baer MR; Stuart BC; Shenolikar RA; Gore SD
J Oncol Pract; 2015 Mar; 11(2):e190-8. PubMed ID: 25563701
[TBL] [Abstract][Full Text] [Related]
39. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
[TBL] [Abstract][Full Text] [Related]
40. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
Glynn A; Hernandez I; Roberts ET
Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]